Known targets — ChEMBL curated mechanism
PPARDPTGS1PTGS2dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Lysine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.61 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.43 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.43 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.43 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 9/20 | 0.42 |
| ▸ | DPP8 | Q6V1X1 | 5/20 | 0.42 |
| ▸ | DPP9 | Q86TI2 | 5/20 | 0.42 |
| ▸ | DPP4 | P27487 | 3/20 | 0.42 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.39 |
| ▸ | FAP | Q12884 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | ARG1 | P05089 | 1/20 | 0.36 |
| ▸ | ARG2 | P78540 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lysine SCHEMBL587922 | 1.00 | GSR (0.61) | GSRRNPEPGNAI3GNAO1GNAI1 | |
| Lysine SCHEMBL17352177 | 0.98 | GSR (0.59) | GSRRNPEPGNAI3GNAO1GNAI1 | |
| Lysine SCHEMBL17352176 | 0.98 | GSR (0.59) | GSRRNPEPGNAI3GNAO1GNAI1 | |
| SCHEMBL31241164 | 0.98 | GSR (0.59) | GSRRNPEPGNAI3GNAO1GNAI1 | |
| Lysine SCHEMBL25283016 | 0.95 | GSR (0.61) | GSRRNPEPGNAI3GNAO1GNAI1 | |
| Lysine SCHEMBL1281705 | 0.95 | GSR (0.61) | GSRRNPEPGNAI3GNAO1GNAI1 | |
| Lysine SCHEMBL5691753 | 0.95 | GSR (0.61) | GSRRNPEPGNAI3GNAO1GNAI1 | |
| Lysine SCHEMBL3427044 | 0.95 | GSR (0.61) | GSRRNPEPGNAI3GNAO1GNAI1 | |
| Lysine SCHEMBL7197544 | 0.95 | GSR (0.61) | GSRRNPEPGNAI3GNAO1GNAI1 | |
| Lysine SCHEMBL1034337 | 0.95 | GSR (0.61) | GSRRNPEPGNAI3GNAO1GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 237 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12564644-B2 | Cyclodextrin complexes of specialized proresolving mediators | THETIS PHARMACEUTICALS LLC (US) | 2026-03-03 | — | — | US | claimed |
| CN-119949497-A | Formula powder containing multiple amino acids and preparation method thereof | 山东美吉客生物科技有限公司 | 2025-05-09 | — | — | CN | claimed |
| EP-4532464-A1 | AGRICULTURALLY USEFUL MINERAL AMINO ACID COMPLEXES | Statera Ag, LLC (US) | 2025-04-09 | — | — | EP | claimed |
| EP-4486393-A2 | CYCLODEXTRIN COMPLEXES OF SPECIALIZED PRORESOLVING MEDIATORS | Thetis Pharmaceuticals LLC (US) | 2025-01-08 | — | — | EP | claimed |
| US-20240408229-A1 | CYCLODEXTRIN COMPLEXES OF SPECIALIZED PRORESOLVING MEDIATORS | THETIS PHARMACEUTICALS LLC (US) | 2024-12-12 | — | — | US | claimed |
| EP-4351609-A1 | ORAL COMPOSITION FOR THE TREATMENT AND/OR PREVENTION OF DISORDERS ASSOCIATED WITH MENOPAUSE | Pizeta Pharma S.P.A. (IT) | 2024-04-17 | — | — | EP | claimed |
| WO-2023230428-A1 | AGRICULTURALLY USEFUL MINERAL AMINO ACID COMPLEXES | STATERA AG, LLC (US) | 2023-11-30 | — | — | WO | claimed |
| WO-2023168245-A2 | CYCLODEXTRIN COMPLEXES OF SPECIALIZED PRORESOLVING MEDIATORS | THETIS PHARMACEUTICALS LLC (US) | 2023-09-07 | — | — | WO | claimed |
| WO-2022259195-A1 | ORAL COMPOSITION FOR THE TREATMENT AND/OR PREVENTION OF DISORDERS ASSOCIATED WITH MENOPAUSE. | PIZETA PHARMA S.p.A. (IT) | 2022-12-15 | — | — | WO | claimed |
| CN-112675160-A | Amino acid mineral salt trace element composition and preparation method thereof | 河北力维素科技有限公司 | 2021-04-20 | — | — | CN | claimed |
| CN-102783691-A | Calcium-magnesium hydrogen producing agent | ZHILIN LI | 2012-11-21 | — | — | CN | claimed |
| EP-2416786-A1 | PHOSPHATE-BINDING MAGNESIUM SALTS AND USES THEREOF | Cypress Pharmaceutical, Inc. (US) | 2012-02-15 | — | — | EP | claimed |
| US-20110045063-A2 | PHOSPHATE-BINDING MAGNESIUM SALTS AND USES THEREOF | CYPRESS PHARMACEUTICAL, INC. (US) | 2011-02-24 | — | — | US | claimed |
| CN-101913237-A | Manufacturing method of high-temperature resistant and corrosion-resistant polyphenyl thioether composite tube | XUN CHEN | 2010-12-15 | — | — | CN | claimed |
| US-7815943-B2 | Cardiovascular therapy composition including transfer factor and therapeutic methods including use of the composition | 4LIFE RESEARCH, LC (US) | 2010-10-19 | — | — | US | claimed |
| WO-2010117370-A1 | PHOSPHATE-BINDING MAGNESIUM SALTS AND USES THEREOF | CYPRESS PHARMACEUTICALS, INC. (US) | 2010-10-14 | — | — | WO | claimed |
| US-20090269399-A1 | PHOSPHATE-BINDING MAGNESIUM SALTS AND USES THEREOF | CYPRESS PHARMACEUTICAL, INC. (US) | 2009-10-29 | — | — | US | claimed |
| CN-100405924-C | Magnesium supplementing feed additive having controlled slow-release type magnesium, its preparation and use method | UNIV ZHEJIANG (CN) | 2008-07-30 | — | — | CN | claimed |
| US-20070243232-A1 | Method to treat and prevent asthma attacks using throat lozenges and orally-retained liquids containing magnesium | EBY III GEORGE A | 2007-10-18 | — | — | US | claimed |
| CN-1823610-A | Magnesium supplementing feed additive having controlled slow-release type magnesium, its preparation and use method | UNIV ZHEJIANG (CN) | 2006-08-30 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240408229-A1 | CYCLODEXTRIN COMPLEXES OF SPECIALIZED PRORESOLVING MEDIATORS | PTGER1, LTB4R2, ALOX5 | GSR 1794/4885RNPEP 2760/4885GNAI3 1591/4885 |
| US-12564644-B2 | Cyclodextrin complexes of specialized proresolving mediators | ALOX15, ALOX12, PTGES | GSR 2736/4885RNPEP 3892/4885GNAI3 2830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.